KDR and neoplasm: Secondly, apatinib can highly selectively bind and strongly inhibit VEGFR2, reduce tumor angiogenesis, further inhibit recurrence and metastasis caused by tumor hypoxia after TACE surgery, and apatinib can also regulate immune suppression through anti-angiogenesis, enhance the antitumor activity of ICI drugs, and effectively reduce the RCCEP induced by camrelizumab, all of which can improve the clinical benefit of patients (12–14, 26, 28, 29).